FUSN — Fusion Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.80bn
- $1.61bn
- $2.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.11 | ||
| Price to Tang. Book | 8.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 872.73 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.8% | ||
| Return on Equity | -49.34% | ||
| Operating Margin | -4798.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.44 | 1.46 | 2.07 | 0.46 | 0.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.
Directors
- Mohit Rawat PRE
- John Valliant CEO
- John Crowley CFO
- Eric Burak CTO
- Christopher Leamon CSO (54)
- Maria Stahl OTH
- Donald Bergstrom DRC (49)
- Johan Christenson DRC (64)
- Barbara Duncan DRC (56)
- Philina Lee DRC
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 22nd, 2014
- Public Since
- June 26th, 2020
- No. of Shareholders
- 136
- No. of Employees
- 113
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 84,692,585
- Address
- 270 Longwood Rd. S, HAMILTON, L8P 0A6
- Web
- https://fusionpharma.com/
- Phone
- +1 2897990891
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for FUSN
Fusion Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Fusion Pharmaceuticals Inc Earnings Release
Similar to FUSN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Fusion Pharmaceuticals share price?
As of Today at 19:08 UTC, shares in Fusion Pharmaceuticals are trading at $21.31. This share price information is delayed by 15 minutes.
How has the Fusion Pharmaceuticals share price performed this year?
Shares in Fusion Pharmaceuticals last closed at $21.31 and the price had moved by +424.88% over the past 365 days. In terms of relative price strength the Fusion Pharmaceuticals share price has outperformed the S&P500 Index by +323.89% over the past year.
What are the analyst and broker recommendations for Fusion Pharmaceuticals?
The overall consensus recommendation for Fusion Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Fusion Pharmaceuticals dividend yield?
Fusion Pharmaceuticals does not currently pay a dividend.
Does Fusion Pharmaceuticals pay a dividend?
Fusion Pharmaceuticals does not currently pay a dividend.
When does Fusion Pharmaceuticals next pay dividends?
Fusion Pharmaceuticals does not currently pay a dividend.
How do I buy Fusion Pharmaceuticals shares?
To buy shares in Fusion Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fusion Pharmaceuticals?
As of the previous close price of $21.31, shares in Fusion Pharmaceuticals had a market capitalisation of $1.80bn.
Where are Fusion Pharmaceuticals shares listed?
Here are the trading details for Fusion Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: FUSN
What kind of share is Fusion Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Fusion Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fusion Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Fusion Pharmaceuticals is $21.67. That is 1.69% above the last closing price of $21.31.
Analysts covering Fusion Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.44 for the next financial year.
What is the trend in the Fusion Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fusion Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +340.47%.
As of the last closing price of $21.31, shares in Fusion Pharmaceuticals were trading +190.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fusion Pharmaceuticals PE Ratio?
The Fusion Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $21.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fusion Pharmaceuticals?
Fusion Pharmaceuticals' management team is headed by:
- Mohit Rawat - PRE
- John Valliant - CEO
- John Crowley - CFO
- Eric Burak - CTO
- Christopher Leamon - CSO
- Maria Stahl - OTH
- Donald Bergstrom - DRC
- Johan Christenson - DRC
- Barbara Duncan - DRC
- Philina Lee - DRC